ArticleSarcoma2011
Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets.
Article in Sarcoma, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 52 citations in OpenAlex.
- Proof of Concept of the Radiosensitizing Effect of Gadolinium Oxide Nanoparticles in Cell Spheroids and a Tumor-Implanted Murine Model of Chondrosarcoma.International journal of nanomedicine · 2022Trial
- Expanded methods for geometric location of 2D bone histology co-registration in 3D radiology volumes.Physical and engineering sciences in medicine · 2026Article
- The Double Life of microRNAs in Bone Sarcomas: Oncogenic Drivers and Tumor Suppressors.International journal of molecular sciences · 2025Review
- A novel perspective on bone tumors: advances in organoid research.Frontiers in pharmacology · 2025Review
- Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies.Cancers · 2023Review
- MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells.Frontiers in oncology · 2023Article
- Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death.Molecular cancer therapeutics · 2022Article
- Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence.Therapeutic advances in medical oncology · 2022Article
- Tumor Suppressive Role of miR-342-5p in Human Chondrosarcoma Cells and 3D Organoids.International journal of molecular sciences · 2021Article
- Review
- Clinical Statistical Analysis with Comparison between Pelvic and Non-pelvic Chondrosarcoma.Oman medical journal · 2021Article
- The transcription co-factor JAB1/COPS5, serves as a potential oncogenic hub of human chondrosarcoma cellsAmerican journal of cancer research · 2021Article
- SOX9 Knockout Induces Polyploidy and Changes Sensitivity to Tumor Treatment Strategies in a Chondrosarcoma Cell Line.International journal of molecular sciences · 2020Article
- Selective Agonists of Nuclear Retinoic Acid Receptor Gamma Inhibit Growth of HCS-2/8 Chondrosarcoma Cells.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2020Article
- Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair.Cancer management and research · 2020Article
- Prognostic nomograms to predict overall survival and cancer-specific survival in patients with pelvic chondrosarcoma.Cancer medicine · 2019Article
- Revisiting the Role of Radiation Therapy in Chondrosarcoma: A National Cancer Database Study.Sarcoma · 2019Article
- Unique and overlapping GLI1 and GLI2 transcriptional targets in neoplastic chondrocytes.PloS one · 2019Article
- Molecular Targeted Therapy Approach to Musculoskeletal Tumors.Techniques in orthopaedics (Rockville, Md.) · 2018Article
- Triggering of cancer cell cycle arrest by a novel scorpion venom-derived peptide-Gonearrestide.Journal of cellular and molecular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chondrosarcoma, a primary malignancy of bone, has eluded successful treatment with modern chemotherapeutic and radiation regimens. To date, surgical resection of these tumors remains the only curative treatment offered to patients with this diagnosis. Understanding and exploring the nature of chemotherapy and radiation resistance in chondrosarcoma could lead to new molecular targets and more directed therapy for these notoriously difficult-to-treat tumors. Here we review the most current hypotheses regarding the molecular mechanisms mediating chemotherapy and radiation resistance and the future direction of chondrosarcoma therapy research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.